<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534105</url>
  </required_header>
  <id_info>
    <org_study_id>IRB07-121</org_study_id>
    <nct_id>NCT00534105</nct_id>
  </id_info>
  <brief_title>Lipid Metabolism in Gestational Diabetes</brief_title>
  <official_title>Study of Lipid Metabolism in Gestational Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baystate Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baystate Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine if, during pregnancy, women with GDM have an
      exaggerated lipid response compared to non-gestational diabetics. If a difference is noted,
      further studies will explore the possibility of screening gestational diabetics during their
      pregnancy for hyperlipidemia to determine if prenatal screening can predict postpartum risk
      for hyperlipidemia. In addition the relationship, if any between maternal lipid dysfunction
      and placental disease will be explored.

      This will be a prospective cohort study. As part of routine prenatal care, women receive a
      one hour glucose challenge test to screen for gestational diabetes. Those women with elevated
      values then require a three hour glucose tolerance test, which is a diagnostic test for
      gestational diabetes. All women that are scheduled to receive a three hour GTT will be
      identified and ask to enroll in this study. 46 women whose three hour GTT is normal and thus
      do not have GDM, will be compared to 46 women with an abnormal three hour GTT and thus would
      have the diagnosis of GDM. Enrolled women will have a lipid panel consisting of; total
      cholesterol, triglycerides, HDL and LDL cholesterol at the time of their fasting glucose
      blood sample. In addition, a repeat lipid panel will be sent at the time of the third hour
      sample, to assess changes, if any due to the glucose challenge. Umbilical cord blood samples
      will be sent in order to obtain newborn lipid profiles. Women in both the GDM and normal
      groups will be asked to return 6-8 weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot study is to determine if, during pregnancy, women with GDM have an
      exaggerated lipid response compared to non-gestational diabetics. If a difference is noted,
      further studies will explore the possibility of screening gestational diabetics during their
      pregnancy for hyperlipidemia to determine if prenatal screening can predict postpartum risk
      for hyperlipidemia. In addition the relationship, if any between maternal lipid dysfunction
      and placental disease will be explored. Subsequent studies could also explore the possible
      perinatal complications associated with elevated lipids and or metabolic syndrome.

      C. Experimental Design, Methodology and Expected Results

      Study Design:

      We propose a prospective cohort design.

      Study Population:

      All women that are scheduled to receive a three hour GTT to rule out gestational diabetes
      would be identified and ask to enroll in this study. Specifically, eligible patients will be
      women who failed their glucose challenge test (GCT) and are scheduled for the follow-up three
      hour glucose tolerance test (GTT). The GCT is routinely performed among all prenatal care
      patients at 24-28 wks gestation. The 3 hour GTT requires patients to be fasting overnight. A
      fasting blood glucose is sampled, and the patients are given a 100 gram glucose drink. Serum
      glucose samples are then taken at one, two and three hours after the glucose loading. The
      &quot;exposed&quot; group will be defined as women diagnosed with GDM (elevated glucose values on two
      or more samples in the three hour GTT). The &quot;unexposed&quot; group will be defined as women with
      no abnormal glucose values in the three hour GTT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>Postpartum</time_frame>
    <description>Cholesterol values were obtained at least 6 weeks postpartum from the gestational diabetic group and the normal controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglyceride Values</measure>
    <time_frame>Postpartum</time_frame>
    <description>Triglyceride values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL</measure>
    <time_frame>Postpartum</time_frame>
    <description>Triglyceride values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL</measure>
    <time_frame>Postpartum</time_frame>
    <description>LDL values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">106</enrollment>
  <condition>Gestational Diabetes</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Gestational Diabetics</arm_group_label>
    <description>Patients with Gestational Diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Normal pregnant women without gestational diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Total Cholesterol</intervention_name>
    <arm_group_label>Gestational Diabetics</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Triglyceride</intervention_name>
    <arm_group_label>Gestational Diabetics</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HDL</intervention_name>
    <arm_group_label>Gestational Diabetics</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LDL</intervention_name>
    <arm_group_label>Gestational Diabetics</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnancy

          -  Abnormal one hour glucose challenge test

          -  &quot;Normal&quot; controls group one hour test between 135 mg% and 150 mg%

          -  &quot;Gestational diabetic&quot; group with two abnormal values on a 3 hour GTT

        Exclusion Criteria:

          -  History of diagnosis of diabetes, hypertension, heart disease or chronic renal disease

          -  Prior history of lipid disorder or metabolic syndrome

          -  Current medications thought to adversely influence glucose tolerance (i.e. prednisone
             or other steroids and systemic beta-mimetic drugs)

          -  Non-singleton pregnancy

          -  &lt; 16 years of age or over 40 years of age

          -  Not planning to deliver at Baystate Medical Center

          -  Twins
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn R Markenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baystate Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2007</study_first_submitted>
  <study_first_submitted_qc>September 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <results_first_submitted>July 2, 2013</results_first_submitted>
  <results_first_submitted_qc>July 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 11, 2013</results_first_posted>
  <last_update_submitted>July 2, 2013</last_update_submitted>
  <last_update_submitted_qc>July 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baystate Medical Center</investigator_affiliation>
    <investigator_full_name>Glenn Markenson</investigator_full_name>
    <investigator_title>Director, Maternal Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Gestational diabetes</keyword>
  <keyword>Hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pregnant patients presenting for gestational diabetes screening</recruitment_details>
      <pre_assignment_details>Only uncomplicated obstetrical patients</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gestational Diabetics</title>
          <description>Patients with Gestational Diabetes with a lipid screening performed during the pregnancy.</description>
        </group>
        <group group_id="P2">
          <title>Normal Pregnancies</title>
          <description>Normal pregnant women without gestational diabetes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gestational Diabetics</title>
          <description>Patients with Gestational Diabetes with a lipid screening performed during the pregnancy.</description>
        </group>
        <group group_id="B2">
          <title>Normal Pregnancies</title>
          <description>Normal pregnant women without gestational diabetes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Age at Recruitment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="30" upper_limit="36"/>
                    <measurement group_id="B2" value="30" lower_limit="26" upper_limit="34"/>
                    <measurement group_id="B3" value="31" lower_limit="28" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cholesterol</title>
        <description>Cholesterol values were obtained at least 6 weeks postpartum from the gestational diabetic group and the normal controls</description>
        <time_frame>Postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gestational Diabetics</title>
            <description>Patients with Gestational Diabetes with a lipid screening performed during the pregnancy.</description>
          </group>
          <group group_id="O2">
            <title>Normal Pregnancies</title>
            <description>Normal pregnant women without gestational diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol</title>
          <description>Cholesterol values were obtained at least 6 weeks postpartum from the gestational diabetic group and the normal controls</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204" lower_limit="139" upper_limit="330"/>
                    <measurement group_id="O2" value="201" lower_limit="169" upper_limit="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride Values</title>
        <description>Triglyceride values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.</description>
        <time_frame>Postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gestational Diabetics</title>
            <description>Patients with Gestational Diabetes with a lipid screening performed during the pregnancy.</description>
          </group>
          <group group_id="O2">
            <title>Normal Pregnancies</title>
            <description>Normal pregnant women without gestational diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride Values</title>
          <description>Triglyceride values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" lower_limit="74" upper_limit="174"/>
                    <measurement group_id="O2" value="83" lower_limit="52" upper_limit="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL</title>
        <description>Triglyceride values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.</description>
        <time_frame>Postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gestational Diabetics</title>
            <description>Patients with Gestational Diabetes with a lipid screening performed during the pregnancy.</description>
          </group>
          <group group_id="O2">
            <title>Normal Pregnancies</title>
            <description>Normal pregnant women without gestational diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>HDL</title>
          <description>Triglyceride values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="41" upper_limit="57"/>
                    <measurement group_id="O2" value="57" lower_limit="52" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL</title>
        <description>LDL values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.</description>
        <time_frame>Postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gestational Diabetics</title>
            <description>Patients with Gestational Diabetes with a lipid screening performed during the pregnancy.</description>
          </group>
          <group group_id="O2">
            <title>Normal Pregnancies</title>
            <description>Normal pregnant women without gestational diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>LDL</title>
          <description>LDL values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" lower_limit="110" upper_limit="154"/>
                    <measurement group_id="O2" value="120" lower_limit="83" upper_limit="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gestational Diabetics</title>
          <description>Patients with Gestational Diabetes with a lipid screening performed during the pregnancy.</description>
        </group>
        <group group_id="E2">
          <title>Normal Pregnancies</title>
          <description>Normal pregnant women without gestational diabetes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Glenn Markenson MD</name_or_title>
      <organization>Baystate Medical Center</organization>
      <phone>413-794-8073</phone>
      <email>glenn.markenson@bhs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

